Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 52-Week High - Still a Buy?

Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $28.56 and last traded at $28.43, with a volume of 256773 shares. The stock had previously closed at $27.65.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Wedbush reissued an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Finally, Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $38.80.

Kiniksa Pharmaceuticals Trading Up 0.7 %

The firm has a market cap of $1.96 billion, a P/E ratio of -192.56 and a beta of 0.07. The firm's 50 day moving average is $22.20 and its two-hundred day moving average is $21.37.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. Kiniksa Pharmaceuticals's quarterly revenue was up 72.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.25) EPS. Analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ross Moat sold 18,259 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the sale, the insider now owns 9,415 shares in the company, valued at approximately $191,030.35. This represents a 65.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 224,820 shares of company stock valued at $5,386,361 in the last 90 days. 54.57% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. JPMorgan Chase & Co. acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $4,997,000. SG Americas Securities LLC acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter valued at $355,000. Charles Schwab Investment Management Inc. grew its stake in Kiniksa Pharmaceuticals by 36.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock worth $2,414,000 after buying an additional 32,393 shares in the last quarter. Raymond James Financial Inc. bought a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $3,955,000. Finally, Globeflex Capital L P raised its holdings in shares of Kiniksa Pharmaceuticals by 217.1% during the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after buying an additional 60,656 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.